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Evaluation of a bispidine-based chelator for gallium-68 and of the 
porphyrin conjugate as PET/PDT theranostic agent 
Dr Thomas W. Price,[a,b] Dr Steven Y. Yap,[c] Dr Raphaël Gillet,[d] Huguette Savoie,[c] Dr Loïc J. 
Charbonnière,[d] Prof. Ross W. Boyle,*[c] Dr Aline M. Nonat,*[d] Dr Graeme J. Stasiuk*[a,b] 
 
Abstract: In this study a bispidine ligand has been applied to the 
complexation of gallium(III) and radiolabelled with gallium-68 for the 
first time. Despite its 5-coordinate nature, the resulting complex is 
stable in serum for over two hours, demonstrating a ligand system 
well matched to the imaging window of gallium-68 positron emission 
tomography (PET). To show the versatility of the bispidine ligand and 
its potential use in PET, the bifunctional chelator was conjugated to a 
porphyrin, producing a PET/PDT-theranostic, which showed the same 
level of stability to serum as the non-conjugated gallium-68 complex. 
The PET/PDT complex killed >90% of HT-29 cells upon light 
irradiation at 50 µM. This study shows bispidines have the versatility 
to be used as a ligand system for gallium-68 in PET. 
Introduction 
Positron emission tomography (PET) is a highly sensitive imaging 
technique with high tissue penetration.[1–3] This technique can 
allow for the in vivo imaging of diseased tissues by targeting 
biochemical processes; thus allowing for detection of disease 
before physical changes occur. Recently, gallium-68 (68Ga) has 
found significant interest as a PET radionuclide due to its 
generator based production allowing for ease of access.[3–5] 
Incorporation of 68Ga into a radiotracer is typically achieved 
through the use of a chelator that complexes the PET isotope.[3,6,7] 
When designing these chelators, special attention must be 
brought to the three following points: (i) they should form a unique 
radiolabeled complex, ideally in mild conditions; (ii) with high 
kinetic/thermodynamic stability; and (iii) strong resistance to 
hydrolysis and to transchelation reactions, occurring in particular 
with transferrin, and to transmetallation or competition with metals 
such as Cu(II) or Zn(II). Despite numerous attempts and studies 
only a few ligands fulfill all the criteria.[6–8] These ligands are 
depicted in Figure 1. DOTA (1,4,7,10-tetraazacyclododecane-
N,N’,N’’,N’’’-tetraacetic acid) and its conjugates (with octreotide 
and derivatives) are clinically in use for imaging neuroendocrine 
tumours[9] although they require high temperatures and acidic 
conditions for radiolabeling.[10][11]The triazacyclononane derivative 
(NOTA), its analogue with phosphinic pendant arms (TRAP) and 
the acyclic chelator H2dedpa also need acidic conditions but no 
heating.[6,12–14] All these chelators are however subject to 
competition with Cu(II) and Zn(II),[15,16] although TRAP displays an 
apparent improved selectivity for Ga(III).[13] 6-amino-1,4-
diazepine triacetate (DATA) chelators[17] as well as siderophores 
(such as deferoxamine),[18] N,N'-Bis(2-
hydroxybenzyl)ethylenediamine-N,N'-diacetic acid (HBED)[18]and 
tris(hydroxypyridinone) (THP)[18] have the advantage to be 
radiolabeled in a wide pH range, THP being the most promising 
as quantitative radiochemical yields can be obtained in mild 
conditions.[19,20] Several THP-bioconjugates have been studied in 
vivo, demonstrating either very promising tumor/body ratio[21,22] or 
disappointing results.[23,24] These observations demonstrate that 
both radiocomplex and biological vector have a synergic effect on 
the biodistribution of the radiopharmaceutical. 
For all these considerations, it is of high interest to 
investigate the potential of other families of ligands such as 
bispidines. Bispidines (chelators based on a 3,7-
diazabicyclo[3.3.1]nonane core) are widely used chelators with a 
highly preorganised coordinating site (Figure 1).[25,26] They have 
been used to complex a range of metals, including radiometals 
such as 64Cu, complexes of which were found to be remarkably 
inert.[27,28] Their application to Ga(III) complexation, and 
particularly 68Ga complexation, remains relatively unexplored.[29] 
 The field of theranostics aims at developing agents with 
combined therapeutic activity and diagnostic properties in a single 
agent.[30] Such theranostic agents allow for monitoring the uptake 
and real-time distribution of the therapeutic agent, the progression 
of the disease, as well as the therapeutic response. This enables 
an individualized treatment strategy which has been shown to be 
very efficient in selecting the optimal treatment, limiting adverse 
reactions, and implementing optimal dosing regimes.[31–33] In the 
case of cancer, “smart agents” with targeted drug delivery 
systems to the tumor are considered as a very promising 
alternative to conventional treatment, the effectiveness of which 
is limited by their absence of specificity. For these drugs, triggered 
by externally applied stimuli (e.g. radiation or light), monitoring 
their uptake and distribution is vital to optimize their application as 
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it will allow for the appropriate timing of their trigger, hence 
maximizing their effectiveness. 
 Photodynamic therapy (PDT) is an example of such a 
therapeutic technique in which a drug is administered, and then 
an external trigger (in this case irradiation with a high intensity 
light source, such as a laser) causes the therapeutic effect. PDT 
agents are typically photosensitizers that are activated by 
absorption of visible light which first populate their excited singlet 
state and then, after energy transfer, their long-lived excited triplet 
state. This triplet state can undergo photochemical reactions in 
the presence of oxygen to form reactive oxygen species (ROS), 
including singlet oxygen.[34] The localized production of these 
highly reactive species in the diseased tissues further causes the 
destruction of the neoplasm. Thus, PDT can allow for highly 
targeted toxicity with minimal off-target toxicity by only irradiating 
the target tissue.[34] Tetrapyrrole structures such as porphyrins, 
chlorins, bacteriochlorins and phthalocyanines derivatives have 
been widely investigated in PDT.[35] Porphyrins have been 
selected in this study due to their low toxicity, high phototoxicity, 
ease of synthesis, and innate tumour targeting properties.[34,36–40] 
 In view of the multimodal biomedical applications of 
metalloporphyrin, and in particular for PET/PDT purposes, 68Ga 
has also been used previously with porphyrins.[41–47] Work in this 
area started with the incorporation of 68Ga into the porphyrin core 
directly; however this involved vigorous heating using a 
microwave for efficient radiolabeling.[41–44] Furthermore, this 
prevents the incorporation of other metals into the porphyrin cavity, 
reducing the options available for optimizing the system.[48] More 
recent work has therefore involved conjugating a chelator to the 
porphyrin and then radiolabeling the chelator.[45,46] First 
experiments were performed using DOTA and NOTA. However, 
although they are commonly used for 68Ga complexation, they 
were only poorly labelled when conjugated to the porphyrin.[45] 
The acyclic chelator H3Dpaa was able to be readily radiolabeled 
with 68Ga when conjugated to a porphyrin;[46] however, the 
resulting complex was insufficiently stable.[46,49] As for 
bioconjugates, there is a need of finding a good chelator/porphyrin 
match in order to optimize both radiolabeling and PET imaging 
properties and PDT efficiency. 
 In this study we investigated the ability of a bispidine 
chelator to complex Ga(III) and to be radiolabeled with 68Ga. 
Further, we conjugated this chelator to a water soluble porphyrin 
and assessed the resulting conjugate’s potential as a PET/PDT 
theranostic agent. 
Results and Discussion 
Complex Synthesis: The bispidine ligand, L1, was prepared as 
previously described.[28] This pentadentate ligand is expected to 
coordinate to Ga(III) via the two ternary amines of the 
diazabicyclononane, the two nitrogen of the pyridyl groups and 
the acetate arm, in a similar fashion to that observed  with Zn(II) 
for an analogue of L1 bearing a glycine substituent instead of the 
(L)-lysine.[27] Complexation of Ga(III) by L1 was performed at pH 
4.5 at reflux (Scheme 1). Upon complexation of Ga(III), the pyridyl 
protons are significantly deshielded (Figure 2), with a downfield 
shift of 0.3-0.8, indicating the donation of electrons from the ring 
due to complexation of the cationic metal. The methyl group 
attached to the amine of the bispidine ring is also significantly 
deshielded (CH3, ΔδH = 0.9 ppm); this suggests that the amine of 
the ring is involved in complexation. The proton alpha to the 
carboxylate of the lysine unit (H10) is also greatly shielded; with an 
upfield shift of 1.2 ppm (Figure S1).  
 The backbone of the cyclic structure is also locked in place, 
as by the coordination of the carboxylate giving an asymmetric 
nature evidenced by many of the resonances corresponding to 
protons in these environments; the resonances of H2 and H4 are 
distinct; these are also significantly deshielded compared to the 
analogous resonances in the free ligand with an upfield shift of 
1.1 ppm. The proton at the apex of the ligand ring structure (H9) 
is also deshielded by 0.7 ppm. Protons in the 6 and 8 positions 
show geminal coupling of 13.5 Hz and are also deshielded.  
Radiochemistry: Radiolabeling of L1 with 68Ga was followed by 
radio-TLC. Achieving a high radiochemical yield required heating 
due to the rigid nature of the chelator. Furthermore, an acidic pH 
was required for effective radiolabeling; pH 4 was found to be 
optimal (Figure 3a), likely due to the formation of kinetically inert 
Ga(III) hydroxides at higher pHs.[4,50] A relatively high ligand 
concentration was also required; a radiochemical yield of 89% 
was achieved at a ligand concentration of 100 µM whereas at 200 
µM a radiochemical yield of 94% was achieved (Figure 3b). These 
results are comparable to those previously reported for 
macrocyclic chelators such as DOTA, which shows a 95% RCY 
under similar conditions (upon heating at 85 °C at pH 4.0 for 30 
minutes with a 100 μM ligand concentration)[3,51,52] In terms of 
complexation kinetics and radiolabeling efficiency, ligand L1 is not 
as efficient as NOTA (95% RCY are obtained with no heating at 
pH 3.5 for 10 minutes with a 10 μM ligand concentration) and the 
phosphinic analogue TRAP,[13] which can be radiolabeled at much 
lower concentrations (c < 3μM, 5 min, pH 3.2) at 95°C or even at 
room temperature when using a large excess of ligand. A similar 
trend is observed, when comparing to acyclic ligands such as 
THP (5 min, pH 6.5 at 25°C), H2dedpa (5-10 min, pH 4.5 at 25°C) 
and H3dpaa (99% RCY, pH 4.5, 25°C at 110 μM ligand 
concentration). These differences are not surprising when looking 
at the chemical structure of ligand L1, which is a pentadentate 
ligand and therefore not optimized for Ga(III) complexation in 
terms of kinetic, selectivity and thermodynamic stability.  
However, based on previous observations with 64Cu-
analogues,[53] promising results in terms of kinetic inertness were 
expected when using a bispidine scaffold. This was indeed the 
case when assessed for radiochemical stability against foetal 
bovine serum (FBS) no decomplexation was observed over 2 
hours incubation at 37oC (Figure S5). This is the ideal imaging 
window time for gallium-68’s half-life, thus showing that the 
bispidine chelator is suitable for translation to in vivo PET 
applications with 68Ga. In addition, it is foreseen that 
radiochemical yields and labelling conditions may be further 
improved by utilizing other bispidine derivatives, in particular with 
hexadentate coordination mode. 
Conjugation to porphyrin: To show the bispidine ligand can be 
utilized for applications in PET, not only as a chelator for gallium-
68 but as a functional tool, we conjugated the ligand to a water-
soluble porphyrin to produce a PET/PDT theranostic agent. L1 






was coupled to a water soluble porphyrin through the terminal 
lysine residue. The NHS-ester of the water soluble porphyrin, L2, 
was prepared as previously described[46,54,55] and the amide bond 
formation was undertaken in DMF. Following semi-preparative 
HPLC purification, the desired bispidine-porphyrin conjugate, L3, 
was obtained in a 48% yield (Scheme 2). Conjugate formation 
was confirmed by mass spectrometry (m/z = 405.3 [M]3+, Figure 
S11). 
It is evident from the 1H NMR (Figure S9) that the product contains 
both porphyrin and bispidine moieties; the aromatic porphyrin 1H 
resonances, corresponding to 24 protons, are evident at δH = 9.46, 
9.04 and 8.29 for the three pyridyl units and the beta hydrogens 
of the porphyrin ring. The bispidine is evident through the 
additional aromatic resonances, corresponding to 8 protons, at 
7.48 and 8.70 due to the pyridyl arms. 
Conjugate complexation reaction: Complexation of Ga(III) was 
undertaken under the same conditions as for L1. Evidence for 
complexation was obtained from the 1H NMR of the complex due 
to the increased shielding of the bispidine pyridyl protons 
(downfield shift of 0.3 ppm). The retention of the protons within 
the porphyrin ring (δH = -3.08) confirms that complexation did not 
take place within the porphyrin ring (Figure S12). While 
complexation of Ga(III) by porphyrins has been previously 
reported,[42] this required more forcing conditions such as 
microwave heating and as such complexation within the porphyrin 
ring was not expected. 
Radiolabelling of conjugate: Radiolabelling of the conjugate, L3, 
was achieved under the optimized conditions determined for the 
ligand L1. Complete complexation of the 68Ga was achieved by 
200 µM L3 at pH 4.5 within 15 minutes when heated to 95 oC. This 
radiolabelled conjugate was assessed for its stability in FBS – all 
of the activity was retained within the complex over 2 hours 
(Figure S15). As a control, the porphyrin L2 was radiolabeled 
under the same conditions; radiochemical yields <30% were 
achieved, showing that the conjugate L3 has a selectivity for 68Ga 
in the bispidine chelator, with a stability to FBS within the PET 
imaging window. 
 
Phototoxicity: To assess the viability of this system as a potential 
theranostic agent, the photo- and cytotoxicities of both the 
conjugate, L3, and the Ga(III) complex, [Ga(L3)], were assessed 
in human adenocarcinoma (HT-29) cells (Figure S16). Cells were 
incubated with either L3 or [Ga(L3)] at varying concentrations and 
irradiation was carried out using a constant dose of visible light 
(20 J cm-2; 400-700 nm). The results were compared to a non-
irradiated control. Although in a clinical setting red light is more 
commonly used for PDT, clinical lasers used for PDT are 
significantly more powerful than the quartz tungsten halogen light 
source used in this study. To compensate for the lower power, 
white light was used covering the whole porphyrin absorbance 
band including the strong Soret band at 422 nm. 
 Under these conditions, >90% cell death was seen at a 
concentration of 50 µM for [Ga(L3)] when irradiated (Figure 4). 
Minimal dark toxicity was observed at all concentrations tested. 
This shows phototoxicity at a similar concentration to Photofrin®, 
a clinically relevant porphyrin PDT agent, in HT-29 cells.[56] 
Conclusions 
We describe the application of a bispidine ligand, L1, to the 
complexation of Ga(III). Furthermore, we demonstrate that this 
ligand can be successfully radiolabeled with 68Ga producing a 
serum stable complex for the first time. Radiolabeling required 
high temperature (95oC) and concentrations (200 µM) to achieve 
near-quantitative yields (94%). Although a higher ligand 
concentration than traditional chelators for gallium-68, further 
optimization of the denticity of the ligand and of the functional 
groups attached to the bispidine core may improve upon this in 
the future.[25] 
 The bifunctional bispidine, L1, was conjugated to a water-
soluble porphyrin; the resulting conjugate, L3, was also applied to 
gallium(III) complexation and radiolabeling was achieved under 
the same conditions as for L1. These conditions are milder than 
those previously reported for insertion of 68Ga into the porphyrin 
core as microwave heating was not required. Furthermore, 1H 
NMR analysis of the Ga(III) complex confirms the presence of the 
protons within the porphyrin ring; this confirms that the 
radiolabeling is taking place at the chelator site and not at the 
porphyrin site. This will allow for future developments of this 
system to potentially incorporate alternate metals into the 
porphyrin ring. 
 L3 and [Ga(L3)] were shown to have low toxicity in the 
absence of light. Upon irradiation these systems were significantly 
more toxic with over 90% of HT-29 cells being killed by 50 µM of 
[Ga(L3)], and 79% by L3, upon irradiation. 
 This work demonstrates the viability of the bispidine 
framework for Ga(III) complexation and radiolabeling with 68Ga for 
applications in PET imaging. The combination of bispidine and 
porphyrin produces a PDT agent that can be effectively 
radiolabeled with 68Ga to produce a serum stable theranostic 
probe for PET/PDT. 
Experimental Section 
NMR spectra were recorded on a JEOL ECP 400 MHz/JEOL Lambda 
400 MHz spectrometer using the residual protic solvent signal as an 
internal reference. Chemical shifts are given in ppm (δ) and coupling 
constants (J) are given in Hertz (Hz). Mass spectrometry data were 
obtained from the EPSRC National Mass Spectrometry Facility at 
Swansea University. UV-vis spectroscopy was carried out on a Varian 
Cary 50 Bio UV-vis spectrophotometer. pH measurements were 
carried out using a Jenway model 3520 pH/mV/temperature meter 
with a three point calibration. All commercially available starting 
material used in synthesis were obtained from Sigma Aldrich, 
Fluorochem, and Alfa Aesar and were used without further purification. 
Deionised water was obtained from a Millipore Milli-Q reagent water 
system. All solvents were obtained from Fisher Scientific and VWR. 
HPLC analysis were performed on Agilent HPLC system. The 
separations were performed on a Gemini® 5μm C18 110 Å LC column 
150×4.6 mm (Phenomenex, UK) at a flow rate of 1 mL min-1, with a 
mobile phase consisting of 0.1% TFA in water (solvent A) and 0.1% 
TFA in acetonitrile (solvent B). Gradient [time/min](solvent A:solvent 
B): [0-2](95:5). [2-3](95:5 – 78:22). [3-23](78:22 – 77:23). [23-
24](77:23 – 70:30). [24-25](70:30 – 5:95). [25-26](5:95). [26-27](5:95 
– 95:5). [27-30](95:5). 






Radiochemistry: The IGG100 generator was eluted with 0.6 M aq. 
HCl (3 mL). This eluate (300–200 MBq) was diluted with H2O (15 mL) 
and passed through a Strata-X-C 33 μM Cation Mixed-mode 
polymeric support. The activity was liberated from the column using 
98:2 acetone:0.1 M aq. HCl (1 mL). Aliquots (∼30 MBq) of this solution 
were dried under a stream of inert gas at 90 °C and allowed to cool 
before use. 100 µL of ligand solution was added to the dried 68Ga and 
shaken at the appropriate temperature. 5 μL aliquots were taken for 
analysis by TLC. TLC analysis was performed on Kieselgel 60 F254 
plates (Merck) with an eluate of 0.1 M citric acid in water. 100 μL of 
radiolabelling solution was added to 1.5 mL of foetal bovine serum 
and incubated at 37 °C. Aliquots were taken every 30 minutes for TLC 
analysis. 
Cytotoxicity assays: A stock solution was made by dissolving L3 or 
[Ga(L3)] in medium (2 mL). The stock was sterilized by filtration 
through 0.22 μm PES syringe filter unit (Millex-GP). The concentration 
of the stock was calculated by UV-vis spectroscopy using the 
extinction coefficient of the conjugate. The stock was diluted further 
with medium to give the desired concentration range. 800 μl of the 
appropriate cells (HT-29 colon adenocarcinoma, adjusted to a 
concentration of 1x106 cells /ml in medium with L-glutamine, was 
added to 200 μL conjugate solution in a 12×75 mm polystyrene FACS 
tube (Falcon). The cells were allowed to incubate in the dark for 1 hour 
at 37 °C and 5% CO2, after which they were centrifuged with 3× 
excess of medium to remove unbound L3 or [Ga(L3)]. The pellet of 
cells was resuspended in 1 ml medium and 4 x100 μl of each 
concentration was put in two 96 wells plates. One plate was irradiated 
with white light to a dose of 20 J cm-2 while the other serves as a dark 
control. After irradiation, 5 μl of foetal bovine serum (FBS) was added 
to each well and the plates are returned to the incubator overnight. 
After 18 to 24 hours, the cell viability was determined using 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) 
colorimetric assay. 10 μL of 12 mM MTT solution was added to each 
well and incubated between 1 and 4 hours at 37 °C to allow MTT 
metabolisation. The crystals formed were dissolved by adding 150 μL 
of acid-alcohol mixture (0.04M HCl in absolute 2-propanol). The 
absorbance at 570 nm was measured on a Biotek ELX800 Universal 
Microplate Reader. The results were expressed with respect to control 
values 
Synthesis of [Ga(L1)]: L1 (21 mg, 33.6 μmol) was dissolved in water 
(5 mL). GaCl3 (11.8 mg, 67.2 μmol) was added and the pH adjusted 
to 4.0 with NaOH and HCl. The solution was heated to reflux for 20 
hours before being concentrated. The white solid was washed with 
acetonitrile before being dissolved in 1:1 Acetonitrile:water, filtered, 
and dried to give a white solid (18 mg, 90% ). 1H NMR (400 MHz, D2O, 
298 K), δ: 8.75 (br s, 2 H, Ha), 8.37 (t, 1 H, Hc, 
3JHH = 7.8 Hz), 8.31 (t, 
1 H, Hc, 
3JHH = 7.6 Hz), 8.02 (d, 1 H, Hb/Hd, 
3JHH = 7.8 Hz), 7.81 – 7.92 
(m, 3 H, Hb, Hd), 5.52 (s, 1 H, H2/H4), 5.48 (s, 1 H, H2/H4), 4.48 (s, 1 H, 
H9), 3.41 (d, 1 H, H10, 
3JHH = 8.9 Hz), 3.36 (d, 1 H, H6/H8, 
2JHH = 13.7 
Hz), 3.14 (d, 1 H, H6/H8, 
2JHH = 13.3 Hz), 2.88 (br s, 2 H, H14), 2.67 (d, 
1 H, H6/H8, 
2JHH = 13.5 Hz), 2.59 (d, 1 H, H6/H8, 
2JHH = 13.5 Hz), 2.45 
(s, 3 H, -CH3), 1.70 (br s, 1 H, - CH2-), 1.59 (br s, 4 H, - CH2-), 1.29 
(br s, 1 H, -CH2-). 
13C NMR (100 MHz, D2O, 298 K), δ: 175.14, 171.35, 
171.14, 151.31, 151.04, 147.09, 144.50, 128.21, 128.03, 70.58, 68.69, 
64.29, 63.79, 57.81, 51.55, 51.26, 50.79, 46.16, 38.99, 26.68, 24.52, 
22.83. MS (ESI) m/z: 297.58 [M]2+ 
Synthesis of L3: L2 (50 mg, 42 µmol) and L1 (50 mg, 80 µmol) were 
taken up in dry DMF (5 mL) and triethylamine (50 µL, 360 µmol) was 
added. The reaction was allowed to proceed at room temperature 
overnight protected from light. Solvent was removed under reduced 
pressure and the reaction was purified using semi-preparative HPLC. 
The solvent was concentrated under reduced pressure, washed with 
diethyl ether, and dried under vacuum. The residue was precipitated 
by addition of diethyl ether over a methanol solution to yield a purple 
solid (27 mg, 20 µmol, 48%). 1H NMR (400 MHz, DMSO-d6) δ: 9.46 
(s, 6H, porphyrin-m-Py), 9.16-8.92 (m, 14H, βH, porphyrin-o-Py), 
8.81-8.52 (m, 2H, bispidine-Py), 8.29 (d, J = 16.4 Hz, 4H, porphyrin-
o,m-Ph), 7.00-7.08 (m, 6H, bispidine-Py), 5.02 (br s, 2H), 4.69 (s, 9H, 
N-CH3), 3.95 (2, 1H), 3.60-3.43 (m, 4H), 3.20-2.94 (m, 4H), 2.28-1.51 
(m, 8H), -3.06 (s, 2H, NH). 13C NMR (100 MHz, DMSO-D6) δ: 204.09, 
198.95, 198.73, 172.05, 166.35, 158.37, 158.06, 156.99, 149.46, 
148.08, 144.76 (βC), 137.45, 135.04, 132.66 (βC), 127.03, 126.58, 
126.22, 123.33, 123.19, 122.42, 119.43, 118.86, 116.43, 115.26, 
75.01, 74.27, 67.65, 62.26, 61.38, 58.60, 50.57, 48.29, 44.07, 43.32, 
42.06, 29.27, 19.70. MS (ESI) m/z: 405.3 [M]3+, HRMS (ESI) m/z: 
405.1727 (calculated for C71H67N12O8 405.1729). UV-Vis (H2O), nm: 
422, 519, 558, 582, 639. ԑ(422 nm) = 258300 M-1 cm-1. 
Synthesis of [Ga(L3)]: L3 (1 mg, 0.76 µmol) was dissolved in water 
(0.4 mL). To this solution was added acetate buffer (pH 4.5, 1 M, 50 
µL) and a solution of GaCl3 (70 µL, 57 mM, 4.0 µmol). The reaction 
was allowed to proceed overnight at 100 ºC. Concentration of the 
reaction solution, followed by purification by semi-preparative HPLC, 
yielded the product as a purple solid. 1H NMR (400 MHz, DMSO-d6) δ 
9.49 (s, 6H, porphyrin-m-Py), 9.23-8.67 (m, 16H, bispidine-Py, βH, 
porphyrin-o-Py), 8.62 (s, 1H, bispidine-Py), 8.42-8.11 (m, 6H, 
bispidine-Py, porphyrin-o,m-Ph), 7.94-7.64 (m, 3H, bispidine-Py), 
5.48-4.99 (m, 2H), 4.69 (s, 9H, N-CH3), 4.04 (s, 1H), 3.10-2.52 (m, 
4H), 2.36-0.70 (m, 12H), -3.08 (s, 2H, NH). MS (ESI), m/z: 433.8 [M-
3Cl+H2O]
3+, HRMS (ESI), m/z: 433.8077 (calculated. for 
C71H66GaN12O9 433.8107). UV-Vis (H2O) nm: 422, 519, 556, 585, 640. 
ԑ(422 nm) = 240000 M-1 cm-1. 
Keywords: Gallium-68• Bispidine • PET • PDT • theranostic 
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Scheme 1. Complexation of Ga(III) by bispidine L1. 
  







Figure 2. 1H NMR (400 MHz, 298 K) of A) L1 (d4-MeOH) and B) [Ga(L1)] (D2O, pD = 5.4).Figure Caption. 
 
  







Figure 3. Radiolabelling of L1 with 68Ga. A) Effect of pH and temperature on radiolabelling. [L1] = 100 µM, t = 15 minutes, I = 0.1 M NH4OAc. B) Effect of concentration 
on radiolabelling. pH = 4, T = 95 oC, t = 15 minutes, I = 0.1 M NH4OAc. 
 
  







Scheme 2. Synthesis and radiolabelling of L3 to produce a PET/PDT theranostic agent. 
 
  







Figure 4. Toxicity of [Ga(L3)] in HT-29 cells as measured by MTT assay. Solid line indicates irradiated toxicity, dashed line indicates non-irradiated toxicity. 
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